Click it and Unblock the Notifications
Latest Updates
-
Who Was Mithu Mukherjee? Veteran Bengali Actress Passes Away At 71 -
Ahmedabad Police Flag Fraud Risk Behind Viral 'Rent A Garba Partner' Ads -
Vidya Balan’s Jailer 2 Entry As Kantha: From Silk To Manjulika, A Look At Her Unconventional Roles -
Samay Raina Has Now Denied Dating Rumours With Two Women In Three Months -
Kareena Kapoor Turns 46: From Size Zero To Fine Lines, The ‘Daayra’ Actress Is Choosing To Age Without Apology -
The Emotional Side of Delayed Parenthood That We Don’t Talk About Enough -
World Alzheimer’s Day 2026: Why Early Diagnosis Matters And What This Year’s Theme Means -
When Is Navratri In 2026? Full Dates, Rituals, Colours, Significance, and Fasting Guide -
Vijay Sethupathi Confirms Maharaja 2, Hollywood Remake In The Works -
Dashavatara Vrat 2026: Everything To Know About Tithi, Rituals, Fasting And The Ten Forms Of Lord Vishnu
Molnupiravir Not To Be Included In COVID-19 Clinical Management Protocol: ICMR
The Indian Council of Medical Research (ICMR)'s National Task Force for COVID-19 has decided against including antiviral drug Molnupiravir in the Clinical Management Protocol for COVID-19 as of now, official sources said on Tuesday.
The experts of the task force cited safety concerns and argued that Molnupiravir was not of much benefit in Covid treatment to arrive at the decision in a meeting held on Monday.
According to the Health Ministry, Molnupiravir is an antiviral drug that inhibits SARS-CoV-2 replication by viral mutagenesis. This anti-Covid pill got the Drug Regulator General of India's approval on December 28 for restricted use in emergencies.
"Members of the National Task Force for COVID-19 were not in favour of including the drug in the national treatment guidelines citing that it does not have much benefit in the treatment of coronavirus infection and that there were safety concerns," an official source told PTI.
Indian Council of Medical Research (ICMR) chief Dr Balram Bhargava had last week said that Molnupiravir has major safety concerns. He added that WHO and the UK have not included it for treatment.
"We have to remember that this drug has major safety concerns. It can cause teratogenicity, mutagenicity and cartilage damage. It can damage the muscles also.
"Contraception will have to be done for three months for male and female if this drug is given because the child born could be problematic due to teratogenic influence," he had said.
The UK Medicines and Healthcare products Regulatory Agency had on December 4 granted approval for Molnupiravir under special conditions for treatment of mild to moderate COVID-19 in adults who have at least one risk factor for developing severe illness.
USFDA on December 23 granted Emergency Use Authorisation for the drug for treating mild-to-moderate COVID-19 in adults at high risk for progression to severe disease, including hospitalization or death, and for whom alternative treatment options are not accessible or clinically appropriate.
According to conditions, the drug should be sold by retail only under the prescription of medical specialists and the recommended dose should be 800 mg twice daily for five days.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.
Continue with Google
